Dimerix (ASX:DXB) recruited the first paediatric patient for the phase-three clinical trial for DMX-200, the company's drug candidate for kidney disease, according to a Thursday filing with the Australian bourse.
The biopharmaceutical company is assessing the efficacy and safety of DMX-200 in patients with focal and segmental glomerulosclerosis (FSGS), a rare disease that attacks the kidney's filtering units, per the filing.
A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK, and the US will recruit patients into the clinical trial.
The biopharmaceutical company expects the blinded interim analysis in August.
Dimerix's shares were up 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.